Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

The CBD-based cream reduced UVA damage, preventing nuclear and mitochondrial DNA mutations associated with skin ageing and ...

At CTO West Coast, an expert discussed the implications of the FDA’s expedited approval programmes with a spotlight on ...

ANI Pharmaceuticals has commenced a Phase IV trial to compare two dosage levels of Purified Cortrophin Gel for acute gout ...

Endometriosis affects 10%–15% of women of childbearing age, with symptoms such as chronic progressive pelvic pain and ...

The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...

The FDA in the US has granted clearance to BrainStorm to commence a Phase IIIb trial of its NurOwn therapy for ALS.

Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial.

The US FDA has cleared Grifols' investigational new drug (IND) application to commence a Phase II trial of GRF312 Ophthalmic ...

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.